Zurcher Kantonalbank Zurich Cantonalbank Sells 3,400 Shares of Cryolife Inc (NYSE:CRY)

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in shares of Cryolife Inc (NYSE:CRY) by 60.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,245 shares of the medical equipment provider’s stock after selling 3,400 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Cryolife were worth $67,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CRY. Bank of America Corp DE boosted its stake in Cryolife by 11.3% during the 4th quarter. Bank of America Corp DE now owns 123,223 shares of the medical equipment provider’s stock valued at $3,497,000 after purchasing an additional 12,465 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Cryolife by 10.6% in the 4th quarter. Deutsche Bank AG now owns 81,989 shares of the medical equipment provider’s stock worth $2,325,000 after buying an additional 7,847 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in shares of Cryolife by 1,945.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,404 shares of the medical equipment provider’s stock worth $216,000 after buying an additional 7,042 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Cryolife by 205.4% in the 1st quarter. SG Americas Securities LLC now owns 12,707 shares of the medical equipment provider’s stock worth $371,000 after buying an additional 8,546 shares during the last quarter. Finally, Quantamental Technologies LLC purchased a new position in Cryolife during the first quarter valued at $75,000. 71.70% of the stock is owned by institutional investors and hedge funds.

Shares of CRY stock traded down $0.53 during trading hours on Friday, reaching $26.03. 2,658 shares of the company’s stock were exchanged, compared to its average volume of 191,047. The stock’s 50 day moving average is $28.67 and its 200-day moving average is $29.21. The company has a market cap of $980.89 million, a price-to-earnings ratio of 99.69 and a beta of 0.62. The company has a current ratio of 5.03, a quick ratio of 3.82 and a debt-to-equity ratio of 0.83. Cryolife Inc has a fifty-two week low of $23.99 and a fifty-two week high of $36.05.

Cryolife (NYSE:CRY) last issued its quarterly earnings results on Tuesday, July 30th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.03. The business had revenue of $71.14 million for the quarter, compared to the consensus estimate of $70.79 million. Cryolife had a return on equity of 3.85% and a net margin of 0.87%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. Equities analysts anticipate that Cryolife Inc will post 0.29 EPS for the current year.

In other news, VP Scott B. Capps sold 2,000 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $28.55, for a total transaction of $57,100.00. Following the transaction, the vice president now directly owns 141,079 shares of the company’s stock, valued at $4,027,805.45. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.40% of the company’s stock.

Several research analysts have issued reports on the company. Needham & Company LLC restated a “hold” rating on shares of Cryolife in a research report on Sunday, May 12th. TheStreet lowered Cryolife from a “b-” rating to a “c+” rating in a report on Wednesday, May 22nd. Canaccord Genuity set a $35.00 price objective on shares of Cryolife and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, ValuEngine downgraded shares of Cryolife from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 15th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $31.91.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Further Reading: Holder of Record

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.